Onconetix (NASDAQ:ONCO – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings lowered shares of Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
Check Out Our Latest Report on Onconetix
Onconetix Stock Down 8.5%
About Onconetix
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Recommended Stories
- Five stocks we like better than Onconetix
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
